Respiratory Tract Infection Clinical Trial
Official title:
Impact of Respiratory Virus Infections and Bacterial Microbiome Shifts on Lymphocyte and Respiratory Function in Infants Born Prematurely or Full Term
This clinical study will investigate the relationships between sequential respiratory viral infections, patterns of intestinal and respiratory bacterial colonization, and adaptive cellular immune phenotypes which are associated with increased susceptibility to respiratory infections and long term respiratory morbidity in preterm and full term infants. This is a prospective, cohort study, enrolling at a single center via two sites (URMC and URMC-affiliated Highland Hospital and Rochester General Hospital). Enrollment will be accomplished in approximately 15 - 36 months. The study will enroll 280 subjects, 150 pre-term and 130 full-term.
This clinical study will investigate the relationships between sequential respiratory viral infections, patterns of intestinal and respiratory bacterial colonization, and adaptive cellular immune phenotypes which are associated with increased susceptibility to respiratory infections and long term respiratory morbidity in preterm and full term infants. This is a prospective, cohort study, enrolling at a single center via two sites (URMC and URMC-affiliated Highland Hospital and Rochester General Hospital). Enrollment will be accomplished in approximately 15 - 36 months. The study will enroll 280 subjects, 150 pre-term and 130 full-term. This protocol does not study an agent or intervention. However, the bronchodilator, albuterol, a beta 2 agonist, will be administered as part of the Respiratory Inductive Plethysmography (RIP) pulmonary function assessments. All infants will remain in the study up to 3 years plus 17 weeks, depending on gestational age at birth. The full-term infants are expected to be typically developing newborns and generally healthy. Enrolled newborns will have a sample of cord blood (CB) for evaluation of lymphocyte phenotype and baseline neutralizing antibody titers. Maternal saliva samples will be collected to test exposure to environmental tobacco smoke. A nose, throat and rectal swab will be obtained for the assessment of the respiratory and gut microbiome and testing for known respiratory pathogens and pathogen discovery. Prior to hospital discharge, infants will have an evaluation of lymphocyte phenotype and function, and will undergo a respiratory assessment via RIP prior to and after a bronchodilator. Co-morbidities, familial and environmental risk factors for atopy, asthma and respiratory symptoms will be assessed. Following hospital discharge, all babies (full-term and former preterm infants) will be followed longitudinally through 3 years CGA as outpatients. During the first year of follow-up, all infants will have rectal and nose, throat swabs obtained monthly. Screening for symptomatic respiratory dysfunction and illnesses will also occur during the time of follow-up as per schedule. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00240461 -
Use of COLD-fX to Prevent Respiratory Infections in Community Dwelling Seniors
|
Phase 3 | |
Completed |
NCT03524118 -
Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)
|
Phase 1/Phase 2 | |
Recruiting |
NCT02568800 -
Prolonged Infusion Cefepime and Nosocomial Infections
|
Phase 3 | |
Completed |
NCT00427141 -
A Three-Part Study Of GSK580416 In Healthy Subjects
|
Phase 1 | |
Completed |
NCT04071158 -
A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS
|
Phase 2 | |
Completed |
NCT00688610 -
Antibiotics in Patients With Acute Respiratory Tract Infection With Procalcitonin as Parameter
|
Phase 2 | |
Completed |
NCT01549938 -
Cholecalciferol Intervention to Prevent Respiratory Infections Study
|
Phase 2 | |
Terminated |
NCT03572062 -
A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults
|
Phase 2 | |
Completed |
NCT04424316 -
A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
|
Phase 3 | |
Completed |
NCT01129765 -
Home Usability of a Nasal Lavage System in Children
|
N/A | |
Completed |
NCT01787227 -
A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel
|
N/A | |
Completed |
NCT02210156 -
Effects of a Supplement on Acute Respiratory Infections
|
N/A | |
Completed |
NCT01075204 -
Clarithromycin Modified Release Observational Study for Evaluation of Treatment, Tolerability & Recovery Time in Saudi & Egyptian Clinical Settings (CLOSER)
|
N/A | |
Completed |
NCT00585481 -
Incidence of Severe Respiratory Syncytial Virus Infections in Preterm Brazilian Children
|
N/A | |
Completed |
NCT05337163 -
A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
|
||
Completed |
NCT00812422 -
The Efficacy and Safety of Dexibuprofen Syrup
|
Phase 3 | |
Active, not recruiting |
NCT02087761 -
A Multi-Site Clinical Evaluation of the ARIES Flu Assay in Symptomatic Patients
|
N/A | |
Completed |
NCT01076153 -
Recovery Time in Thai Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR
|
N/A | |
Completed |
NCT00265187 -
The Prevalence and Clinical Manifestations of Human Metapneumovirus Among Children With Bronchiolitis.
|
N/A | |
Completed |
NCT04032093 -
A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN
|
Phase 2 |